What good is a cure if you can't get it to the people
who need it the most?

There is promising research sitting on a shelf as we speak.

We need your help to start saving lives.


I want to help

Targeting Inflammatory Bowel Disease with Nanoparticles

Details

. Targeting Inflammatory Bowel Disease with Nanoparticles. Approximately 3.6 million people in the US and Europe suffer from inflammatory bowel disease. There is no cure, and the standard treatment has serious side effects. The AvrA protein is produced by Salmonella typhimurium, a pathogen that is a major cause of human gastroenteritis. It inhibits the NF-kappaB and JNK MAPK pathways, thereby suppressing inflammatory and apoptotic responses. We have formulated AvrA protein nanoparticles with diameters of ~100 nm. Therefore these AvrA protein nanoparticles can serve as both the therapeutic and the delivery vehicle. Initial in vivo studies show that AvrA nanoparticles reduce inflammation in mouse models of acute inflammation and colitis.

The AvrA protein is produced by Salmonella typhimurium, a pathogen that is a major cause of human gastroenteritis. It inhibits the NF-kappaB and JNK MAPK pathways, thereby suppressing inflammatory and apoptotic responses. We have formulated AvrA protein nanoparticles with diameters of ~100 nm. Therefore these AvrA protein nanoparticles can serve as both the therapeutic and the delivery vehicle. Initial in vivo studies show that AvrA nanoparticles reduce inflammation in mouse models of acute inflammation and colitis.

Read more

Discussion

Most Recent
Log in here to vote or comment

  • Miia Burke —

    Very important. My daughter has a bowel disease which has no cure at the moment. There has been very little research for it.